These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 25028731)

  • 1. Reply to "Risk for invasive fungal infections during acute myeloid leukemia induction therapy: a true association with echinocandins?".
    Kontoyiannis DP; Lewis RE
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4990-1. PubMed ID: 25028731
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk for invasive fungal infections during acute myeloid leukemia induction therapy: a true association with echinocandins?
    Marini BL; Perissinotti AJ; Huang AM; Frame DG; Kaul DR
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4988-9. PubMed ID: 25028730
    [No Abstract]   [Full Text] [Related]  

  • 3. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011.
    Gomes MZ; Mulanovich VE; Jiang Y; Lewis RE; Kontoyiannis DP
    Antimicrob Agents Chemother; 2014; 58(2):865-73. PubMed ID: 24277033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal prophylaxis associated with decreased induction mortality rates and resources utilized in children with new-onset acute myeloid leukemia.
    Fisher BT; Kavcic M; Li Y; Seif AE; Bagatell R; Huang YS; Zaoutis T; Torp K; Leckerman KH; Aplenc R
    Clin Infect Dis; 2014 Feb; 58(4):502-8. PubMed ID: 24270167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifungal Prophylaxis With Posaconazole Is Effective in Preventing Invasive Fungal Infections in Acute Myeloid Leukemia Patients During Induction and Salvage Chemotherapy.
    Wong GC; Abdul Halim NA; Tan BH
    Clin Infect Dis; 2015 Oct; 61(8):1351-2. PubMed ID: 26139846
    [No Abstract]   [Full Text] [Related]  

  • 7. Systemic antifungal prophylaxis reduces invasive fungal in acute myelogenous leukemia: a retrospective review of 833 episodes of neutropenia in 322 adults.
    Rex JH; Anaissie EJ; Boutati E; Estey E; Kantarjian H
    Leukemia; 2002 Jun; 16(6):1197-9. PubMed ID: 12040453
    [No Abstract]   [Full Text] [Related]  

  • 8. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.
    Park H; Youk J; Shin DY; Hong J; Kim I; Kim NJ; Lee JO; Bang SM; Yoon SS; Park WB; Koh Y
    BMC Cancer; 2019 Apr; 19(1):358. PubMed ID: 30991992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemia.
    Venton G; Adam H; Colle J; Labiad Y; Mercier C; Ivanov V; Suchon P; Fanciullino R; Farnault L; Costello R
    Med Mal Infect; 2016 Jun; 46(4):226-9. PubMed ID: 27126350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.
    Girmenia C; Frustaci AM; Gentile G; Minotti C; Cartoni C; Capria S; Trisolini SM; Matturro A; Loglisci G; Latagliata R; Breccia M; Meloni G; Alimena G; Foà R; Micozzi A
    Haematologica; 2012 Apr; 97(4):560-7. PubMed ID: 22102706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
    Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
    Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia.
    Torres A; Serrano J; Rojas R; Martín V; Martín C; Tabares S; Molina JR; Capote M; Martínez F; Gómez P; Sánchez-García J
    Eur J Haematol; 2010 Mar; 84(3):271-3. PubMed ID: 19878274
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles.
    Dellacasa CM; Busca A; Audisio E; Marmont F; Barbui AM; Falda M; De Rosa FG; Frairia C; Allione B; D'Ardia S; Aydin S; Pecoraro C; Manetta S; Vitolo U
    J Chemother; 2014 Oct; 26(5):315-20. PubMed ID: 24075616
    [No Abstract]   [Full Text] [Related]  

  • 14. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
    Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
    Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
    Abdul-Hamil NA; Wong GC; Nagarajan C; Martinelli G; Cherchione C
    Minerva Med; 2020 Oct; 111(5):443-454. PubMed ID: 32955824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
    Busca A; Lessi F; Verga L; Candoni A; Cattaneo C; Cesaro S; Dragonetti G; Delia M; De Luca A; Guglielmi G; Tumbarello M; Martino G; Nadali G; Fanci R; Picardi M; Potenza L; Nosari A; Aversa F; Pagano L;
    Leuk Lymphoma; 2017 Dec; 58(12):2859-2864. PubMed ID: 28508692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan.
    Tang JL; Kung HC; Lei WC; Yao M; Wu UI; Hsu SC; Lin CT; Li CC; Wu SJ; Hou HA; Chou WC; Huang SY; Tsay W; Chen YC; Chen YC; Chang SC; Ko BS; Tien HF
    PLoS One; 2015; 10(6):e0128410. PubMed ID: 26061179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis.
    Dranitsaris G; Khoury H
    Support Care Cancer; 2011 Nov; 19(11):1807-13. PubMed ID: 20972589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
    Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.
    Ananda-Rajah MR; Grigg A; Downey MT; Bajel A; Spelman T; Cheng A; Thursky KT; Vincent J; Slavin MA
    Haematologica; 2012 Mar; 97(3):459-63. PubMed ID: 22058198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.